These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 116457)

  • 41. [Pigment formation in cultures of Pseudomonas aeruginosa isolated from different pathological material].
    Tydel'skaia IL; Rozhavin MA
    Lab Delo; 1978; (6):363. PubMed ID: 79690
    [No Abstract]   [Full Text] [Related]  

  • 42. Susceptibility of Pseudomonas aeruginosa strains isolated from hospitalized children.
    Patzer J; Walkiewicz R; Dzierzanowska D
    J Antimicrob Chemother; 1986 Jul; 18(1):45-9. PubMed ID: 3093444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Statins inhibit in vitro virulence phenotypes of Pseudomonas aeruginosa.
    Hennessy E; Mooij MJ; Legendre C; Reen FJ; O'Callaghan J; Adams C; O'Gara F
    J Antibiot (Tokyo); 2013 Feb; 66(2):99-101. PubMed ID: 23149514
    [No Abstract]   [Full Text] [Related]  

  • 44. [Virulence factors of Pseudomonas aeruginosa].
    Vaca Pacheco S; Cervantes-Vega C
    Rev Latinoam Microbiol; 1988; 30(2):87-90. PubMed ID: 3146123
    [No Abstract]   [Full Text] [Related]  

  • 45. [Tricentric study of the sensitivity of Pseudomonas aeruginosa serotyping to beta-lactams and aminoglycosides].
    Vachée A; Scheftel JM; Husson MO; Izard D; Ross P; Monteil H
    Pathol Biol (Paris); 1997 May; 45(5):357-62. PubMed ID: 9296084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aminoarabinosylation of Lipid A Is Critical for the Development of Colistin Resistance in Pseudomonas aeruginosa.
    Lo Sciuto A; Imperi F
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Antibiotic sensitivity, serology and typing by pyocine in 154 cultures of Pseudomonas aeruginosa (author's transl)].
    Cantos de la Casa A; García Curiel A; Gómez Fernández MV; Arroyo Trillo A; Díaz Sánchez JA; Dueñas P
    Med Clin (Barc); 1980 Jul; 75(3):104-8. PubMed ID: 6772890
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Serotype and antibiotic sensitivity of Pseudomonas aeruginosa isolated from clinical materials].
    Yoshioka H; Takimoto M; Maruyama S; Furuyama M; Murayama T
    Kansenshogaku Zasshi; 1970 Sep; 44(6):340-4. PubMed ID: 4319797
    [No Abstract]   [Full Text] [Related]  

  • 49. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
    Hocquet D; Muller A; Blanc K; Plésiat P; Talon D; Monnet DL; Bertrand X
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1173-5. PubMed ID: 18180356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Uniformity in sensitivity test media.
    Waterworth PM
    J Antimicrob Chemother; 1978 Jan; 4(1):4-6. PubMed ID: 415034
    [No Abstract]   [Full Text] [Related]  

  • 51. In vitro sensitivity of isolates of Pseudomonas aeruginosa to carbenicillin, gentamicin, tobramycin, and some other antibiotics.
    Wretland B; Nord CE; Wadström T
    Scand J Infect Dis; 1974; 6(1):49-52. PubMed ID: 4208204
    [No Abstract]   [Full Text] [Related]  

  • 52. Characterisation of an IMP-7-producing ST357 Pseudomonas aeruginosa isolate detected in Denmark using whole genome sequencing.
    Hammerum AM; Jakobsen L; Hansen F; Stegger M; Sørensen LA; Andersen PS; Wang M
    Int J Antimicrob Agents; 2015 Feb; 45(2):200-1. PubMed ID: 25511191
    [No Abstract]   [Full Text] [Related]  

  • 53. The in vitro activity of ceftazidime against a multi-resistant serotype 12 Pseudomonas aeruginosa.
    Ninane G; Harper PB
    Infection; 1983; 11 Suppl 1():S16-9. PubMed ID: 6403472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Sensitivity to fosfomycin of multiresistant serotype 012 Pseudomonas aeruginosa. Multicenter study].
    Dubrous P; Cavallo JD; Buisson Y
    Pathol Biol (Paris); 1997 Jun; 45(6):472-8. PubMed ID: 9309262
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and epidemiological correlates of Pseudomonas typing.
    Baltimore RS; Dobek AS; Stark FR; Artenstein MS
    J Infect Dis; 1974 Nov; 130 Suppl(0):S53-9. PubMed ID: 4213951
    [No Abstract]   [Full Text] [Related]  

  • 56. Performance of a commercial microdilution minimal inhibitory concentration procedure for aminoglycoside susceptibility testing of Pseudomonas aeruginosa.
    Etowski DC; Beckwith DG
    Am J Clin Pathol; 1981 Jun; 75(6):830-3. PubMed ID: 6789668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the in-vitro activities of ceftazidime and new cephalosporins against 107 strains of Pseudomonas aeruginosa and 249 strains of cefazolin-resistant Enterobacteriaceae.
    Thabaut A; Durosoir JL; Saliou P
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():123-5. PubMed ID: 19810174
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The penetration of antibiotics through sodium alginate and through the exopolysaccharide of a mucoid strain of Pseudomonas aeruginosa.
    Slack MP; Nichols WW
    Lancet; 1981 Sep; 2(8245):502-3. PubMed ID: 6115250
    [No Abstract]   [Full Text] [Related]  

  • 59. The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.
    Drusano GL; Neely MN; Yamada WM; Duncanson B; Brown D; Maynard M; Vicchiarelli M; Louie A
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249700
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative study of virulence factors among ESβL-producing and nonproducing Pseudomonas aeruginosa clinical isolates.
    Khalil MA; Ibrahim Sonbol F; Mohamed AF; Ali SS
    Turk J Med Sci; 2015; 45(1):60-9. PubMed ID: 25790531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.